Porias CHL, Lamm WL

Language: Spanish
References: 83
Page: 194-206
PDF size: 255.67 Kb.

ABSTRACT

Recent studies confirmed that low levels of testosterone have several common features with the metabolic syndrome such as disturbances in glucose metabolism and insulin secretion, overweight and abdominal fat distribution, lipid disorders and hypertension. The lowest levels of total and free testosterone were found in men with the most pronounced central obesity, measured as waist circumference. Total testosterone was inversely associated with systolic blood pressure, and men with hypertension had lower levels of both total and free testosterone. Furthermore we found that men with diabetes had lower testosterone levels. Epidemiological studies, which in addition have reported a relationship between lipids and cardiovascular risks in men as in coronary heart disease and diabetes are in concordance with insulin resistance and obesity. Insulin resistance is a major risk factor for atherosclerosis. Animal studies have demonstrated that testosterone reduces the insulin resistance, visceral fat and atherosclerosis so far that hormone substitution therapy in men may contribute to be protective beside the sexual benefits.

REFERENCES

1. Pozor MA, Mc Donell SM. Color doppler ultrasound evaluation of testicular flow in stallions. Theriogenology 2004; 61: 799-810.

2. Colpi GM, Mancini M, Pidiferro G, Scroppo FI. Disorders of blood flow: Arterial and venous/sexual dysfunction and varicocele andrology for clinician. Ed Springer (Berlin-Heidelberg) 2006: 978-83.

3. Keenan DM, Veldhius JD. Disruption of the hypothalamic luteinizing hormone pulsing mechanism in aging men. Am J Physiol Regul Integr Comp Physiol 2001; 281: 1917-1924.

4. Vermeulen A, Kaufman JM, Deslypere JP, Thomas G. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab 1993; 76: 1140-6.

5. Van Pottelbergh I, Lumbroso S, Goemaere S, Sultan C, Kaufman J. Lack of influence of the androgen receptor gene CAG-repeat polymorphism on sex steroid status and bone metabolism in elderly men. Clinical Endocrinology 2001; 55: 659-66.

6. Plymate SR, Plymate SR, Tenover JS, Bremner WJ. Circadian variation in testosterone, sex hormone-binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men. Journal of Andrology 1989; 10: 366-71.

7. Vanderschueren D. Partial androgen deficiency of the aging male (PADAM) and testosterone supplementation: use, misuse or abuse? Andrology for the Clinician. (Ed Springer Berlin Heidelberg) 2006: 540-56.

8. Robert C. Dean physiology of penile erection and pathophysiology of erectile dysfunction. Urologic Clinics of North America, 32(4): 379-95.

9. Seftel A. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. The Journal of Urology 2005; 172: 793-94.

10. Porias H, Lamm L. Terapia sustitutiva con testosterona en varón durante el envejecimiento. Revista de Endocrinología y Nutrición SMNE 2007; 15: 8-18.

11. Steen B. Body composition and aging. Nutr Rev 1988; 46: 45-51.

12. Reed RL, Pearlmutter L, Yochum K, et al. The relationship between muscle mass and muscle strength in the elderly. J Am Geriatr Soc 1991; 39: 555-61.

13. Bhasin S, Storer TW, Berman N, Yarasheski KE. B testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 407-13.

14. Shaap LA. Low testosterone levels and decline in physical performance and muscle strength in older men: findings from two prospective cohort studies. Clinical Endocrinology 2007; 10: 1365-75.

15. Goodpaster BH, Park SW, Harris TB, Steven B, Kritchevsky SB, Nevitt M et al. The loss of skeletal muscle strength, mass, and quality in older adults: The health, aging and body composition study (the Health ABC Study). The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2006: 61: 1059-64.

16. Schaap LA, Pluijm SM, Smit JH, van Schoor N, Visser M et al. The association of sex hormone levels with poor mobility, low muscle strength and incidence of falls among older men and women. Clinical Endocrinology 2005; 63: 152-60.

17. Iannuzzi-Sucich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2002; 57: M772-M777.

18. Zi Mian Wang. Whole-body skeletal muscle mass: development and validation of total-body potassium prediction models. American Journal of Clinical Nutrition 2003; 77: 76-82.

19. Sinha-Hikim M, Cornford H, Gaytan MLL, Bhasin S. Effects of testosterone supplementation on skeletal muscle fiber hyperthrophy and satellite cells in community-dwelling older Me. J Clin Endocrinol Metab 2006; 91: 3024-33.

20. Clayton PE, Gill MS, Hall CM, Tillmann V, Whatmore AJ, Price DA. Serum leptin through childhood and adolescence. Clin Endocrinol 1997; 46: 727-33.

21. Shalitin S, Phillip M. Role of obesity and leptin in the pubertal process and pubertal growth a review. Journal of Obesity 2003; 27: 869-74

22. Kaplowitz P. Delayed puberty in obese boys: comparison with constitutional delayed puberty and response to testosterone therapy. J Pediatr 1998; 133: 745-49.

23. Wabitsch M, Blum WF, Muche R, Braun M, Hube F, Rascher W, Heinze E, Teller W, Hauner H. Contribution of androgens to the gender difference in leptin production in obese children and adolescents. J Clin Invest 1997; 100: 808-13.

24. Ellis KJ, Nicolson M. Leptin levels and body fatness in children: effects of gender, ethnicity, and sexual development. Pediatr Res 1997; 42: 484-48.

25. Seidel JC, Bjorntorp P, Sjostrom L, Kvist HR. Visceral fat accumulation in men is positively associated with insulin, glucose and C-peptide levels but negatively with testosterone levels. Metabolism 1990; 39: 897-901.

26. Blum WF, Englaro P, Hanitsch S, Juul A, Hertel N et al. Plasma leptin levels in healthy children and adolescents: dependence on body mass index, body fat mass, gender, pubertal stage, and testosterone. J Clin Endocrinol Metab 1997; 82: 2904-10.

27. Coleman DL. Obesity and diabetes: Two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 1978; 14: 141-8.

28. Harris RB, Hervey E, Hervey GR. Body composition of lean and obese Zucker rats in parabiosis. Int J Obesity 1987; 11: 275-83.

29. Luukkaa V, Pesonen U, Huhtaniemi I, Lehtonen A, Tilvis R, Tuomilehto J, Koulu M, Huupponen R. Inverse correlation between serum testosterone and leptin in men. Journal of Clinical Endocrinology and Metabolism 1998; 83: 3243-46.

30. Behre HM, Simoni M, Nieschlag E. Strong association between serum levels of leptin and testosterone in men. Clinical Endocrinology 1997; 47: 237-40.

31. Pitteloud N, Hardin M, Dwyer AA, Valassi E, Yialamas M, Elahi D, Hayes FJ. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 2005; 90: 2636-41.

32. Tuominen JA, Ebeling P, Stenman U-H, Heiman ML, Stephens TW, Koivisto VA. Leptin synthesis is resistant to acute effects of insulin in insulin-dependent diabetes mellitus patients. J Clin Endocrinol Metab 1997; 82: 381-422.

33. Kirschner MA, Berkowitz R, Ertel NH. Increased estrogen production in obese men. J Clin Endocrinol Metab 1979; 48: 633-38.

34. Raven G, de Jong FH, Kaufman JM, de Ronde W. In men, peripheral estradiol levels directly reflect the action of estrogens at the hypothalamo-pituitary level to inhibit gonadotropin secretion. J Clin Endocrinol Metab 2006; 91: 3324-8.

35. Azria D, Larbouret Ch, Cunat S. Letrozole sensitizes breast cancer cells to ionizing radiation. Breast Cancer Res 2005; 7: R156-63.

36. de Boer H, Verschoor L, Ruinemans-Koerts J, Jansen M. Letrozole normalizes serum testosterone in severely obese men with hypogonadotrophic hypogonadism. Diabetes Obes Metab 2005; 7: 211-15.

37. Tan HM, Low WY. Male health and aging study in multiethnic population; the Asian perpective. The Aging Male 2004; 7: 7-10.

38. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000; 23: 4490-94.

39. Abate N, Haffner SM, Garg A, Peshock RM, Grundy SM. Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab 2002; 10: 4522-4527.

40. Birkeland BI, Hanssen KF, Torjesen PA, Vaaler S. Level of sex hormone-binding globulin is positively correlated with insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 1993; 76: 275-78.

41. Reaven G. Metabolic syndrome pathophysiology and implications for management of cardiovascular disease. Circulation 2002; 106: 286-90.

42. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K et al. Testosterone and sex hormone–binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036-41.

43. Haffner SM, Shaten J, Stem M, Smith GD, Kuller L et al MRFIT Research Group low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. Amer Journ Epidemiology 2996; 143: 889-97.

44. Cohen PG. The hypogonadal-obesity cycle. Medical Hypotheses, (Elsevier) 1999; 52: 49-51.

45. Kaplan AM, Shah A. The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. what are the implications for the relatively high incidence of erectile dysfunction observed in the obese men? The Journal of Urology 2006: 176: 1524-28S.

46. Klentze M. Testosterone: The male hormonal connection treating diabetes and heart disease http://www.anti-aging-med.de/DE/Akademie/frame_AkademieTestos 01.htm

47. Holmang A, Bjorntorp P. The effects of testosterone on insulin sensitivity in male rats. Acta Physiol Scand 1992; 146: 505-10.

48. Stasi R, Abriani L, Beccaglia P, Terzoli E et al. Cancer related fatigue evolving concepts in evaluation and treatment. Cancer 2003; 98: 1-2.

49. Giagulli VA, Kaufman JM, Vermeulen A. Pathogenesis of the decreased androgen levels in obese men. J Clin Endocrinol Metab 1994; 79: 997-00.

50. Rebuffe-Scrive M, Marin P, Bjorntorp P. Effect of testosterone on abdominal adipose tissue in men. Int J Obes 1991; 15: 791-5.

51. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003; 6: 1-7.

52. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European Journal of Endocrinology 2006; 154: 899-906.

53. Trial Information. Summary: A research study for men with diabetes type in and low testosterone. This is approximately a 6-month research study whose purpose is to evaluate the effects of a hormone replacement therapy on men with diabetes type II and low testosterone. Profile Page: University Urology Associates, New York, NY University Urology Associates.

54. Zietz B, Cuk A, Hugl S. Buttner R, Straub RH, Bauer B, Daffner P, Scholmerich J, Palitzsch K. Association of in creased C-peptide serum levels and testosterone in type 2 diabetes. European Journal of Internal Medicine 2000; 11: 322-28.

55. Lima N, Cavaliere H, Knobel M, Halpern A, Medeiros-Neto G. Decreased androgen levels in obese men may be associated with impaired function of the gonadostat. International Journal of Obesity 2000; 24: 1433-7.

56. Khaw KT, Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 1992; 2: 675-82.

57. Tsai EC, Boyco EJ, Leonetti DL, Fujimoto WY. Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. Int Journ of Obesitity 2000; 24: 485-91.

58. Sorva R, Kuusi T, Taskinen MR, Perheentupa J, Nikkilä EA. Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males. Atherosclerosis 1988; 69: 191-7.

59. Gabrielsson BG, Johansson JM, Jennische E, Jernas M, Itoh Y et al. Depot-specific expression of fibroblast growth factors in human adipose tissue. Obesity Research 2004; 210: 608-16.

60. Wauters M, Considine M, Van Gaal L. Human leptin: from an adipocyte hormone to an endocrine mediator. Eur J Endocrinol 2000; 143: 293-311.

61. Holmang A, Bjorntorp P. The effects of testosterone on insulin sensitivity in male rats. Acta Physiologica Scandinavica 1992; 146: 505-10.

62. Gruber DM, Huber JC. Tissue specificity: the clinical importance of steroid metabolites in hormone replacement therapy. Maturitas 2001; 37: 151-7.

63. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc Natl Acad Sci USA 2000; 97: 12729-34.

64. Simpson ER, Mahendroo MS, Means GD et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocrinol Rev 1994; 15: 342-55.

65. Matsumoto T, Kawano H, Shiina H, Sato T, Ka S. Androgen receptor functions in male and female reproduction. Reproductive Medicine and Biology 2007; 6: 11-17.

66. Sato T, Matsumoto T, Yamada T, Watanabe T, Kawano H, Kato S. Late onset of obesity in male androgen receptor-deficient (AR KO) mice. Biochem Biophys Res Commun 2003; 300(1): 167-71.

67. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology and Metabolism 1999; 84: 3666-72.

68. Marin P et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. International Journal of Obesity & Related Metabolic Disorders 1992; 16(12): 991.

69. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 1988; 78: 539-45.

70. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 2000; 21: 890-4.

71. Glueck CJ, Glueck HI, Stroop D, Spiers J, Hamer T, Tracy T. Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidaemic men. J Lab Clin Med 1993; 122: 412-20.

72. Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronaemia with coronary disease in men. Arterioscler Thromb 1994; 14: 701-6.

73. Malkin CJ, Pugh PJ, Jones TH, Channer KS. Testosterone for secondary prevention in men with ischaemic heart disease? Heart 2004; 90: 871-6.

74. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovivk DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 2001; 111: 261-90.

75. Haddad RM, Kennedy CC, Capples SM, Tracz MJ, Boloña ER et al. Testosterone and cardiovascular risk in men: a systematic rewiew and meta- analysis of randomized placebo controlles trials. Mayo Clinic Proc 2007; 82: 29-39.

76. Simon D, Charles MA, Nahoul K, Orssaud G, Kremski J, Hully V, Joubert E, Papoz L, Eschwege E. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. Journal of Clinical Endocrinology and Metabolism 1997; 82: 682-5.

77. English KM, Jones RJ, Jones TH, Morrice AH, Channer KS. Testosterone acts as a coronary vasodilator by a calcium antagonistic action. J Endocrinol Invest 2002; 25: 455-8.

78. English KM, Jones RD, Jones TH et al. Gender differences in the vasomotor effects of different steroid hormones in rat pulmonary and coronary arteries. Horm Metab Res 2001; 33: 645-52.

79. Deenadayalu VP, White RE, Stallone JN et al. Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. Am J Physiol 2001; 281: H1720-7.

80. Webb CM, McNeill JG, Hayward CS et al. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999; 100: 1690-1696.

81. English KM, Jones RJ, Jones TH, Morrice AH, Channer KS. Testosterone acts as a coronary vasodilator by a calcium antagonistic action. J Endocrinol Invest 2002; 25: 455-8.

82. Tipping PG, Hancock WW. Production of tumour necrosis factor and Interleukin-1 by macrophages from human atheromatous plaques. Am J Pathol 1993; 142: 1721-8.

83. Lamm LW, Porias H. La próstata como riesgo principal en la aplicación de un tratamiento hormonal sustitutivo. Revista de Endocrinología y Nutrición 2007; 15: 19-26.